Judith Kim is a Partner in our Patent practice group. For almost 24 years, Ms. Kim has counseled clients innovating in pharmaceuticals, biotechnology, immunology, diagnostics, biofuel, agrosciences, food products, nutraceuticals, cosmetics and personal care. Ms. Kim’s practice includes:
- Preparation of patent applications and their prosecution and appeals worldwide
- Management of foreign oppositions and invalidation trials
- Contested proceedings before the U.S. Patent and Trademark Office
- Opinions on invalidity and noninfringement to ensure freedom to operate
- Due diligences for evaluation of investments and acquisitions, and agreements
Prior to joining Potomac Law, Ms. Kim was a senior partner at a leading IP law firm, where she led legal teams in patent portfolio management, inter partes disputes, licensing and related IP counseling. Ms. Kim’s scientific experiences are in the areas of microbial and mammalian biology. She co-authored eleven scientific publications resulting from her research.
Ms. Kim is an Adjunct Professor at Sogang University Law School in Seoul, Korea.
PREVIOUS SELECTED EXPERIENCE
- Rubin and Rudman, Partner and Chair of IP Practice
- Sterne, Kessler, Goldstein & Fox, Associate and Partner
HONORS AND AWARDS
- LMG Euromoney– Life Sciences “Star” (2012-2015)
- “BioPharma Patent Trends and the Importance of Patent Lifecycle Management,” Global BioPharma Conference, Seoul, Korea, June 2019.
- “Strategic & Transactional – Drafting Globally Compliant Patent Applications:Dream or Reality? An Interactive Discussion,” Practicing Law Institute, NY and SF, April 2019.
- Judith U. Kim and Scott A. Schaller, “IP Flash: Transformative Subject Matter Patent-Eligibility in the US,” European Biotechnology (2015).
- Judith U. Kim and Scott A. Schaller, “After Alice: The Two-Step Rule,” LSIPR Newsletter (2015).
- Judith U. Kim, Paul A. Calvo and Miklos Gaszner, “USPTO Issues New Subject Matter Eligibility Examination Guidelines for Claims Involving Laws of Nature, Natural Principles, Natural Phenomena, and/or Natural Products,” The National Law Review (2014).
- “Lawyers Weigh In On Supreme Court’s Monsanto Ruling,” John Quinn, Law360 Intellectual Property (2013).
- Judith U. Kim, “Possible Far-Reaching Implications of Bowman v. Monsanto,” Intellectual Property Today (2013).
- Judith U. Kim and Jorge A. Goldstein, Ph.D., “In Oral Arguments during Bowman v. Monsanto the Supreme Court Struggles with Exhaustion Doctrine for Patented Seeds,” Sterne, Kessler, Goldstein & Fox (2013).
- Judith U. Kim and Katrina P. Quach, “Trade Secrets – Less Risky Under AIA Prior User Rights?,” Law360 Intellectual Property (2012).
- Eldora L. Ellison, Ph.D. and Judith U. Kim, “Patent Prosecution Strategies for Life Sciences Companies Under the AIA,” Bloomberg Law Reports – Intellectual Property (2012).
- Judith U. Kim and Paul A. Calvo, “Patent Rights From Stem Cell Research Funded By Proposition 71,” Sterne, Kessler, Goldstein & Fox P.L.L.C. (2005).
- Satoh T., Feng P., Kim U.J., Wilber J.F., “Identification of thyrotropin-releasing hormone receptor in the rat testis,” Neuropeptides 27:195-202 (1994).
- Satoh T., Feng P., Kim U.J., Wilber J.F., “Identification of thyrotropin-releasing hormone receptor messenger RNA in the rat central nervous system and eye,” Brain Res. Mol. Brain Res. 19:175-178 (1993).
- Feng P., Gu J., Kim U.J., Carnell N.E., Wilber J.F., “Identification, localization and developmental studies of rat prepro thyrotropin-releasing hormone mRNA in the testis,” Neuropeptides 24:63-69 (1993).
- Carnell N.E., Feng P., Kim U.J., Wilber J.F., “Preprothyrotropin-releasing hormone mRNA and TRH are present in the rat heart,” Neuropeptides 22:209-212 (1992).
- Wilber J.F., Yamada M., Kim U.J., Feng P., Carnell N.E., “The human prepro thyrotropin-releasing hormone (TRH) gene: cloning, characterization, hormonal regulation, and gene localization,” Trans. Am. Clin. Climatol. Assoc. 103:111-119 (1992).
- Feng P., Carnell N.E., Kim U.J., Jacobs S., Wilber J.F., “The human testis: a novel locus for thyrotropin-releasing hormone (TRH) and TRH mRNA,” Trans. Assoc. Am. Physicians 105:222-228 (1992).
- Ambulos N.P. Jr., Kim U.J., Rogers E.J., Lovett P.S., “Constitutive expression of cat-86 associated with a change in the transcription start point,” Gene 105:113-117 (1991).
- Rogers E.J., Kim U.J., Ambulos N.P. Jr., Lovett P.S., “Four codons in the cat-86 leader define a chloramphenicol-sensitive ribosome stall sequence,” J. Bacteriol. 172:110-115 (1990).
- Kim U.J., Ambulos N.P. Jr., Duvall E.J., Lorton M.A., Lovett P.S., “Site in the cat-86 regulatory leader that permits amicetin to induce expression of the gene,” J. Bacteriol. 170:2933-2938 (1988).
- Alexieva Z., Duvall E.J., Ambulos N.P. Jr., Kim U.J., Lovett P.S., “Chloramphenicol induction of cat-86 requires ribosome stalling at a specific site in the leader,” Proc. Natl. Acad. Sci. USA 85:3057-3061 (1988).
- Duvall E.J., Mongkolsuk S., Kim U.J., Lovett P.S., Henkin T.M., Chambliss G.H., “Induction of the chloramphenicol acetyltransferase gene cat-86 through the action of the ribosomal antibiotic amicetin: involvement of a Bacillus subtilis ribosomal component in cat induction,” J. Bacteriol.161:665-672 (1985).